but also reported in lung, breast, ovarian, and prostate cancers.
Celldex Therapeutics' (CLDX) lead product, rindopepimut, which targets EGFRvIII is currently in a Phase III trial in patients with newly diagnosed GBM and a Phase II trial in patients with recurrent GBM. EGFRvIII is expressed in about one third of GBM patients but also reported in lung, breast, ovarian, and prostate cancers. Rindopepimut was partnered with Pfizer earlier, but the rights were returned to Celldex for unspecified reasons. Celldex's deep pipeline includes another product, CDX-1401, in a Phase I/II trial for several cancers. CDX-1401 is an antibody targeting dendritic cells linked to the TAA, NY-ESO-1. This TAA is widely expressed on several tumors: approximately a quarter of all lung, prostate, melanoma, bladder, esophageal, and ovarian cancers.